|
US5703093A
|
|
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5750565A
|
|
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US6201016B1
|
|
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5679546A
|
|
Chimeric proteins which block complement activation
|
|
AU7684594A
|
|
Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
|
|
US5792776A
|
|
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
US5525708A
|
|
Covalent dimer of kit ligand
|
|
US5463083A
|
|
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
|
WO9413802A1
|
|
D4 gene and methods of use thereof
|
|
US5468612A
|
|
9804 gene and methods of use thereof
|
|
EP0656004A1
|
|
Dual functional anti-inflammatory and immunosuppressive agents
|
|
WO9401430A1
|
|
2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
|
|
US5648486A
|
|
Compounds and methods for the treatment of inflammatory and immune disorders
|
|
WO9318136A1
|
|
Process for supporting hematopoietic progenitor cells
|
|
AU3793893A
|
|
Process for supporting hematopoietic progenitor cells
|
|
US5434151A
|
|
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
|
US5358938A
|
|
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
|
WO9215671A1
|
|
Soluble cd28 proteins and methods of treatment therewith
|
